A Phase IV, Randomized, Observer-Blind, Multi-Center, Non Inferiority Comparison of the Immune Response of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Inactivated Split-Virion Influenza Vaccine in Adults Aged Greater Than or Equal to 65 Years.

Trial Profile

A Phase IV, Randomized, Observer-Blind, Multi-Center, Non Inferiority Comparison of the Immune Response of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Inactivated Split-Virion Influenza Vaccine in Adults Aged Greater Than or Equal to 65 Years.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Influenza virus vaccine (Afluria) (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors CSL; Seqirus
  • Most Recent Events

    • 11 Sep 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
    • 11 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov
    • 02 Oct 2008 Actual start date (Oct 2009) added as reported by Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top